An Open-Label, Multicenter, Dose-Escalation, Phase Ia/Ib Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-α (FAP), as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Trial Profile

An Open-Label, Multicenter, Dose-Escalation, Phase Ia/Ib Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-α (FAP), as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2018

At a glance

  • Drugs RO 6874281 (Primary) ; Cetuximab; Trastuzumab
  • Indications Advanced breast cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 25 Jun 2018 Planned End Date changed from 1 Aug 2019 to 18 Aug 2019.
    • 25 Jun 2018 Planned primary completion date changed from 1 Aug 2019 to 18 Aug 2019.
    • 05 Jun 2018 Results (n=35) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top